AquaRMed

Enhancing Water Retention in the Epidermis

 MedPharm’s new exciting proprietary skin hydrating technology moves hydration on to a new level of scientific understanding, leading to a rational formulation design in the efficacious treatment of diseased and dry skin. AquaRMed radically surpasses previous anecdotal evidence-based cosmetic products for skin hydration.

MedPharm’s AquaRMed technology can be easily employed as either a medical device, pharmaceutical or cosmetic for relieving the symptoms of dermatitis and psoriasis, as well a host of other conditions associated with poor skin hydration.

AquaRMed  has shown in studies to offer a notable improvement over the use of commonly used humectants and hydrating agents such as glycerine and hyaluronic acid, as well as the various natural products isolated in extracts from plants. Additionally, in vitro and ex vivo indicates that AquaRMed has anti-proinflammatory properties can can enhance drug permeation and penetration. Such qualities mean AquaRMed could play an important role in medications tackling  xerotic and inflammatory skin conditions.


 Concept to Application

MedPharm is continuing to explore the opportunities for applications of this technology and is happy to open discussions with any interested parties.

This technology could be applied in the following areas:

  • Used as a Medical Device (CE marked) for the control of the symptoms of cutaneous disorders with impaired skin barrier integrity including atopic dermatitis and psoriasis
  • Used as a pharmaceutical treatment of conditions resulting from genetic filaggrin depletion; ichthyosis vulgaris.
  • Used in combination with atopic dermatitis and psoriasis medication to improve efficacy whilst reducing API concentrations
  • Used for the cosmetics industry to radically improve the efficacy of  moisturisers and provide a sound scientific argument based on emulation of the body’s own Natural Moisturising Factor which is often depleted in dry skin

For more information on AquaRMed please contact the MedPharm team.